Moderna set to join S&P 500, stock rallies 8%

Moderna Inc., a biotechnology company catapulted to notoriety after it produced a highly effective COVID-19 vaccine, is set to join the S&P 500 index, a seal of approval that will put the stock in countless index-tracking and actively managed funds and retirement accounts.